JP2025506349A5 - - Google Patents

Info

Publication number
JP2025506349A5
JP2025506349A5 JP2024543542A JP2024543542A JP2025506349A5 JP 2025506349 A5 JP2025506349 A5 JP 2025506349A5 JP 2024543542 A JP2024543542 A JP 2024543542A JP 2024543542 A JP2024543542 A JP 2024543542A JP 2025506349 A5 JP2025506349 A5 JP 2025506349A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
vegf
binder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024543542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506349A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/012083 external-priority patent/WO2023150142A1/en
Publication of JP2025506349A publication Critical patent/JP2025506349A/ja
Publication of JP2025506349A5 publication Critical patent/JP2025506349A5/ja
Pending legal-status Critical Current

Links

JP2024543542A 2022-02-02 2023-02-01 前庭神経鞘腫関連症状を治療するための抗vegf抗体構築物及び関連する方法 Pending JP2025506349A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263305923P 2022-02-02 2022-02-02
US63/305,923 2022-02-02
PCT/US2023/012083 WO2023150142A1 (en) 2022-02-02 2023-02-01 Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms

Publications (2)

Publication Number Publication Date
JP2025506349A JP2025506349A (ja) 2025-03-11
JP2025506349A5 true JP2025506349A5 (enExample) 2026-02-09

Family

ID=85985168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024543542A Pending JP2025506349A (ja) 2022-02-02 2023-02-01 前庭神経鞘腫関連症状を治療するための抗vegf抗体構築物及び関連する方法

Country Status (12)

Country Link
US (1) US20250136673A1 (enExample)
EP (1) EP4473011A1 (enExample)
JP (1) JP2025506349A (enExample)
KR (1) KR20240139075A (enExample)
CN (1) CN118679182A (enExample)
AR (1) AR128422A1 (enExample)
AU (1) AU2023215253A1 (enExample)
CA (1) CA3243517A1 (enExample)
IL (1) IL314656A (enExample)
MX (1) MX2024009456A (enExample)
TW (1) TW202342525A (enExample)
WO (1) WO2023150142A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3086045A1 (en) 2017-12-19 2019-06-27 Akouos, Inc. Aav-mediated delivery of therapeutic antibodies to the inner ear
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
WO2025073297A1 (zh) * 2023-10-06 2025-04-10 甘李药业股份有限公司 表达抗vegf融合蛋白的aav病毒载体及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
EP1007637B1 (en) 1997-04-14 2004-06-30 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant aav product
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
AU6814901A (en) 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
CA2448066A1 (en) 2001-05-31 2002-12-12 Chiron Corporation Chimeric alphavirus replicon particles
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
US7557197B2 (en) 2004-01-28 2009-07-07 Oregon Health & Science University Human soluble neuropilin-1 primary polyadenylation signal and uses thereof
WO2006012414A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Novel polyadenylation signal for use in expression vectors
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
RU2567639C2 (ru) 2009-06-17 2015-11-10 АббВай Биотерапеутикс Инк., Антитела против vegf и их применения
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
JP2015527296A (ja) 2012-03-26 2015-09-17 アメリカ合衆国 哺乳動物細胞へのパッケージングされたrnaの新規の送達
EP2861068A4 (en) 2012-06-01 2016-04-13 Momenta Pharmaceuticals Inc METHODS ASSOCIATED WITH BEVACIZUMAB
US9914770B2 (en) 2013-04-30 2018-03-13 Intas Pharmaceuticals Ltd Cloning, expression and purification method for the preparation of ranibizumab
WO2017050825A1 (en) 2015-09-21 2017-03-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) A method for quantifying bevacizumab
GB201518979D0 (en) 2015-10-27 2015-12-09 Univ Leuven Kath Treatment of hepatic steatosis related oligo-ovulation
IL262207B2 (en) * 2016-04-15 2026-01-01 Univ Pennsylvania Preparations for the treatment of wet age-related macular degeneration
CA3086045A1 (en) * 2017-12-19 2019-06-27 Akouos, Inc. Aav-mediated delivery of therapeutic antibodies to the inner ear
US12558434B2 (en) * 2018-02-20 2026-02-24 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
CN113853437A (zh) * 2018-11-07 2021-12-28 阿库斯股份有限公司 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途
IL303317A (en) * 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA

Similar Documents

Publication Publication Date Title
JP2025004075A (ja) 眼疾患を処置する方法
TWI727279B (zh) 治療眼部疾病之方法
Wilson et al. Radiation-induced astrogliosis and blood-brain barrier damage can be abrogated using anti-TNF treatment
ES2197912T3 (es) Utilizacion de anticuerpos anti-tnf en la preparacion de medicamentos para tratar enfermedades con porcentaje serico elevado de interleucina-6.
AU2007238677B2 (en) Use of IL-I antibodies for treating ophthalmic disorders
US20030012786A1 (en) Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients
AU2002316855B2 (en) Combination therapy using anti-angiogenic agents and TNFalpha
JP2020506924A5 (enExample)
US20200030445A1 (en) Stable formulations of humanized anti-tau antibody
CN102343089B (zh) 一种治疗乳癌的医药组成物
IL292706A (en) Type i interferon inhibition in systemic lupus erythematosus
US7147849B2 (en) Pharmaceutical formulation
TW202237181A (zh) 治療眼部疾病之方法
Jakki et al. The blood brain barrier and its role in Alzheimer's therapy: an overview
CN117159703B (zh) 含抗lag-3抗体的药物组合物及其用途
JP2023551533A5 (enExample)
JP2023542879A5 (enExample)
JP2026077893A (ja) 医薬製剤
JP2024534012A5 (enExample)
JP2024535431A5 (enExample)
US20230132275A1 (en) Use of cdon inhibitors for the treatment of endothelial dysfunction
Rouvas et al. Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration
US11571476B2 (en) Anti-tumor/anti-tumor associated fibroblast/anti-hapten trispecific antibodies and use thereof
CN107614527A (zh) 抗人膜类型adam28抗体
HK40102408A (en) Pharmaceutical composition containing anti-lag-3 antibody and application thereof